H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Zynerba Pharmaceuticals (ZYNE) today and set a price target of $12.00. The company’s shares closed last Tuesday at $3.37, close to its 52-week low of $2.55.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 3.0% and a 49.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Avadel Pharmaceuticals.
Currently, the analyst consensus on Zynerba Pharmaceuticals is a Strong Buy with an average price target of $12.70, a 252.8% upside from current levels. In a report released yesterday, Roth Capital also maintained a Buy rating on the stock with a $8.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.70 and a one-year low of $2.55. Currently, Zynerba Pharmaceuticals has an average volume of 1.52M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
